Genesis Therapeutics is a biotechnology company that invents and deploys breakthrough AI techniques to discover and develop drugs both internally as well as in select partnerships. Genesis has developed Dynamic PotentialNet and other novel neural network algorithms that examine drug-target complexes as flexible, spatial graphs- enabling superior prediction of potency and selectivity of drug candidates. The company's technology offers significant advantages in addressing novel, previously undruggable targets in addition to well-characterized therapeutic targets.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/02/20 | $52,000,000 | Series A |
Felicis Ventures Harpoon Ventures Jazz Venture Partners Jeff Rothschild Mark Leslie Menlo Ventures Radical Ventures Rock Springs Capital  T. Rowe Price Associates Ulu Ventures | undisclosed |
| 08/21/23 | $200,000,000 | Series B |
Andreessen Horowitz BlackRock Fidelity Management & Research Company Menlo Ventures NVentures Radical Ventures Rock Springs Capital T. Rowe Price Associates | undisclosed |
